Journal article icon

Journal article

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.

Abstract:

PURPOSE: Bevacizumab, an anti-VEGFA antibody, inhibits the developing vasculature of tumors, but resistance is common. Antiangiogenic therapy induces hypoxia and we observed increased expression of hypoxia-regulated genes, including carbonic anhydrase IX (CAIX), in response to bevacizumab treatment in xenografts. CAIX expression correlates with poor prognosis in most tumor types and with worse outcome in bevacizumab-treated patients with metastatic colorectal cancer, malignant astrocytoma, an...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
18
Issue:
11
Pages:
3100-3111
Publication date:
2012-06-01
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
Source identifiers:
323067

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP